对PFAS-β-乳糖球蛋白结合机制的结构洞察力介导PFAS毒性
bioRxiv : the preprint server for biology
|February 23, 2026
概括
牛奶蛋白β-乳糖球蛋白在其脂肪酸结合部位结合有毒的per-和多基基物质 (PFAS). 这种由疏水力驱动的相互作用表明,β-乳糖球蛋白可能携带PFAS,可能导致神经毒性.
科学领域:
- 生物化学 生物化学
- 毒理学 毒理学 毒理学
- 结构生物学 结构生物学
背景情况:
- 和多基物质 (PFAS) 是持久的,有毒的环境污染物,由于强大的碳-键.
- 已知一种牛奶蛋白质β-乳糖球蛋白 (BLG) 能运输生物功能必不可少的疏水性化合物.
- 由于潜在的健康影响,了解BLG与PFAS的相互作用至关重要.
研究的目的:
- 研究PFAS与β-乳糖球蛋白的结合机制.
- 确定PFAS与BLG相互作用的结构基础.
- 评估PFAS-BLG复合物的稳定性和亲和力.
主要方法:
- 使用X射线结晶学来确定与PFOA,PFOS和PFDA复杂的BLG的结构.
- 用分子动力学 (MD) 模拟来分析结合的稳定性和能量.
- 在apo-BLG和PFAS-bound BLG之间进行了比较结构分析.
主要成果:
- 晶体结构揭示了BLG的中央体内的PFOA,PFOS和PFDA的高亲和结合,这是已知的视网醇和脂肪酸结合点.
- 疏水性相互作用稳定了PFAS"尾巴"的结合,而与BLG残留物Lys60和Lys69发生极性相互作用.
- MD模拟证实了PFAS结合的稳定性,PFDA表现出最高的结合能 (-25 kcal/mol),这是由于其与更长的疏水链的有利范德瓦尔斯相互作用.
结论:
- β-乳糖球蛋白有效地与PFAS结合,利用其正规的疏水性结合口袋.
- 在PFAS复杂化后,蛋白质的结构经历了构造变化,包括一个开放的EF循环.
- BLG可能充当PFAS的载体,可能影响其分布并调解神经毒性作用.
更多相关视频
08:06The Use of a β-lactamase-based Conductimetric Biosensor Assay to Detect Biomolecular Interactions
Published on: February 1, 2018
9.6K
09:30Analyzing Dynamic Protein Complexes Assembled On and Released From Biolayer Interferometry Biosensor Using Mass Spectrometry and Electron Microscopy
Published on: August 6, 2018
9.9K
相关概念视频
Factors Affecting Protein-Drug Binding: Protein-Related Factors
615
Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
615
Factors Affecting Protein-Drug Binding: Drug-Related Factors
544
Drug binding to proteins is a complex phenomenon influenced by various drug-related factors, each playing a significant role in the interaction between drugs and proteins within the body.
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
One crucial factor in drug-protein binding is the drug's lipophilicity or its affinity for fat. More lipophilic drugs tend to have higher binding extents. For example, highly lipophilic drugs like cloxacillin exhibit substantial protein binding, with as much as 95% of the drug binding to proteins. In...
544
Ligand Binding Sites
15.4K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
15.4K
Ligand Binding and Linkage
5.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.7K
Protein-Drug Binding: Mechanism and Kinetics
1.9K
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
1.9K
Factors Affecting Protein-Drug Binding: Drug Interactions
660
Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
660
